Contents
24 October 2018
Vol 10, Issue 464
Vol 10, Issue 464
Research Articles
- Systems biology–based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma
Systematic drug repositioning identifies digoxin as a potential treatment for groups 3 and 4 medulloblastoma.
- Clostridioides difficile uses amino acids associated with gut microbial dysbiosis in a subset of patients with diarrhea
Increased amino acids in the dysbiotic gut influences susceptibility to Clostridioides difficile infection in mice and humans.
- Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma
DKK3 is produced by the stroma in pancreatic cancer, promotes tumor progression and resistance to therapy, and is a therapeutic target.
- In situ identification of Gram-negative bacteria in human lungs using a topical fluorescent peptide targeting lipid A
A topically administered fluorescently labeled peptide targeting lipid A permits rapid, real-time visualization of bacteria in the distal human lung.
- Antibiotics induce sustained dysregulation of intestinal T cell immunity by perturbing macrophage homeostasis
Antibiotics disrupt intestinal immunity in mice.
Editors' Choice
- Beyond molecular profiling for “precision oncology”
Patient-derived tumor cultures genetically mirror patient tumors, expanding insights into therapeutic resistance.
- Fetal against fatal: In utero genome editing to prevent metabolic disease
In utero CRISPR editing allows early intervention for inborn errors of metabolism in mice.
- That silent alliance: HIV and smoke promote lung diseases
Smoking and HIV independently and synergistically promote pathophysiological changes consistent with chronic lung disease in macaques.
Erratum
About The Cover
ONLINE COVER Outfoxing Medulloblastoma. In addition to carrying a poor prognosis, medulloblastoma groups 3 and 4 are heterogeneous tumors that are difficult to target. Shown here is a species of Digitalis or foxglove, the source of the approved drug digoxin that is used to treat cardiac dysfunction. Huang et al. used systems biology to repurpose drugs for potential use against groups 3 and 4 medulloblastoma. Digoxin prolonged survival, both alone and in combination with radiation, in orthotopic patient-derived xenograft mouse models. Importantly, it did so at concentrations that could be tolerated in humans, indicating that digoxin could be a promising therapeutic avenue for treating these deadly brain tumors. [CREDIT: JEANNE WHITE/SCIENCE SOURCE]
